Pseudohypoparathyroidism

Educational clinical summary of Pseudohypoparathyroidism for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for healthcare professionals and is based on current medical knowledge and evidence-based guidelines. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider, considering the individual patient's circumstances and in consultation with specialists as needed.

Overview

Definition: Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare genetic disorders characterized by target organ resistance to parathyroid hormone (PTH), leading to hypocalcemia and hyperphosphatemia despite inappropriately elevated or normal PTH levels. The key distinguishing feature from true hypoparathyroidism is the elevated PTH in PHP, indicating the body's attempt to overcome the tissue resistance.
Epidemiology: PHP is a rare condition with an estimated prevalence of approximately 1 in 100,000 to 200,000 individuals. There is no significant gender or ethnic predilection, though specific genetic subtypes may have variable frequencies.
Classification: PHP is classified based on the genetic defect and associated clinical features, particularly the presence or absence of Albright's Hereditary Osteodystrophy (AHO). The underlying genetic defect often involves mutations or epigenetic changes in the GNAS gene, which encodes the α-subunit of the stimulatory G-protein (Gsα) involved in signal transduction for PTH and other hormones.
- PHP Type Ia (PHP1A):
  - Most common form with AHO features (see Clinical Presentation).
  - Associated with heterozygous inactivating mutations in the maternal allele of the GNAS gene (exons 1-13).
  - Resistance to multiple hormones that signal via Gsα, including PTH, TSH (thyroid-stimulating hormone), GHRH (growth hormone-releasing hormone), and gonadotropins (FSH/LH), leading to complex endocrine dysfunction.
- PHP Type Ib (PHP1B):
  - No AHO features.
  - Selective PTH resistance.
  - Associated with epigenetic abnormalities (imprinting defects) upstream of the GNAS gene, often affecting the maternal allele. Familial cases are linked to deletions in the STX16 gene locus. Sporadic cases can have loss of methylation at the GNAS-A/B differentially methylated region (DMR).
- PHP Type Ic (PHP1C):
  - Similar clinical presentation to PHP Type Ia (including AHO features and multi-hormone resistance).
  - Normal Gsα activity in vitro (unlike Ia) but defective downstream signaling.
  - Associated with mutations in the GNAS gene, but the exact mechanism for preserved Gsα activity in some assays is not fully understood.
- PHP Type II (PHP2):
  - Very rare, with variable or incomplete PTH resistance.
  - Normal urinary cAMP response to exogenous PTH, but blunted phosphaturic response.
  - Mechanism is poorly understood, likely involves post-cAMP signaling defects. Not associated with GNAS mutations or AHO.
- Pseudo-pseudohypoparathyroidism (PPHP):
  - No PTH resistance (normal calcium, phosphate, PTH).
  - Presence of AHO features.
  - Associated with GNAS mutations, typically inherited from the paternal allele. Since the PTH receptor signaling pathways are maternally imprinted in relevant tissues (e.g., kidney), paternal inheritance of GNAS mutations does not lead to PTH resistance but causes the associated developmental phenotype of AHO.
- Progressive Osseous Heteroplasia (POH):
  - Rare, severe variant of AHO characterized by extensive cutaneous and subcutaneous ossification that progresses into deep muscle.
  - Also caused by inactivating GNAS mutations.

Pathophysiology

Mechanism: The fundamental defect in most forms of PHP is impaired cellular response to PTH at its target tissues (primarily kidney and bone). PTH exerts its effects by binding to the PTH receptor 1 (PTH1R), which is a G-protein coupled receptor. This binding activates the stimulatory G-protein (Gs), leading to increased intracellular cyclic AMP (cAMP) production and downstream signaling cascades.
- In PHP Type Ia, Ib, and Ic, the primary issue lies in the GNAS gene, which encodes the Gsα subunit.
  - PHP Type Ia/Ic: Heterozygous inactivating mutations in GNAS lead to reduced functional Gsα protein. This impacts tissues where the maternal GNAS allele is predominantly expressed (e.g., kidney proximal tubules for PTH effects on phosphate and 1,25-dihydroxyvitamin D synthesis) or where both alleles are expressed but a threshold of Gsα is required. This results in impaired PTH-induced cAMP generation, leading to decreased phosphate excretion, reduced calcium reabsorption in the distal tubules, and decreased 1-alpha hydroxylase activity (impaired 1,25-OH2D production).
  - The multi-hormone resistance (TSH, GHRH, gonadotropins) in PHP Type Ia and Ic occurs because these hormones also signal via Gsα.
  - The AHO features are due to the haploinsufficiency of Gsα in certain developmental tissues, independent of the imprinted expression pattern.
  - PHP Type Ib: Epigenetic defects affecting the imprinting of the GNAS locus lead to reduced expression of the maternal allele in specific tissues, primarily those involved in PTH action (kidney). Unlike PHP Ia, the GNAS gene sequence itself is typically normal, and other hormone resistance is usually absent.
- PHP Type II: The defect occurs downstream of cAMP generation, meaning PTH still stimulates normal cAMP production, but the subsequent cellular responses (e.g., phosphaturia) are blunted. The exact molecular defect is unknown.
Risk Factors: The primary risk factor is the presence of an inactivating mutation or epigenetic defect in the GNAS gene (or other yet-to-be-identified genes in PHP Type II). Inheritance pattern varies (autosomal dominant for most GNAS mutations, complex for imprinting defects in PHP Ib).
Protective Factors: There are no known protective factors as PHP is a genetic condition. Early diagnosis and appropriate management are crucial to mitigate complications.

Clinical Presentation

Signs and Symptoms

The clinical manifestations of PHP are primarily due to chronic hypocalcemia, hyperphosphatemia, and, in PHP Type Ia/Ic, the associated features of Albright's Hereditary Osteodystrophy (AHO).

Cardinal Features:
- Symptoms of Hypocalcemia:
  - Neuromuscular irritability: Paresthesias (tingling around mouth, fingers, toes), muscle cramps, tetany (carpopedal spasm, facial twitching), laryngeal stridor/spasm, generalized seizures (often the presenting symptom in infants/children).
  - Neuropsychiatric: Irritability, anxiety, fatigue, depression, cognitive impairment.
  - Cardiac: QT prolongation on ECG, increasing risk of arrhythmias.
  - Ocular: Cataracts (subcapsular, bilateral).
  - Dental: Enamel hypoplasia, delayed eruption, blunted roots, hypodontia.
- Features of Albright's Hereditary Osteodystrophy (AHO) (in PHP Type Ia, Ic, and PPHP):
  - Short stature: Often disproportionate.
  - Obesity: Truncal obesity, often early onset.
  - Round face: Characteristic facies.
  - Brachydactyly: Shortening of metacarpals (especially 4th and 5th) and metatarsals, leading to dimpling over the affected knuckles when making a fist ("knuckle dimple sign"). This is pathognomonic for AHO.
  - Subcutaneous ossifications: Dystrophic calcifications/ossifications in skin and soft tissues, which can be palpable and sometimes painful.
  - Intellectual disability/developmental delay: Variable severity, typically mild to moderate.
  - Other skeletal anomalies: Short neck, broad skull, genu valgum (knock-knees), exostoses.
- Hormone Resistance (in PHP Type Ia, Ic):
  - Hypothyroidism: Due to TSH resistance (elevated TSH, normal/low free T4/T3).
  - Gonadal dysfunction: Due to FSH/LH resistance (oligomenorrhea/amenorrhea in females, hypogonadism in males).
  - Growth hormone deficiency (functional): Due to GHRH resistance, contributing to short stature.
Early Signs:
- Infantile seizures or tetany.
- Failure to thrive.
- Developmental delay.
- Early onset obesity or characteristic facial features (round face).
- Shortening of digits (brachydactyly) may be noted in early childhood.
Advanced Signs:
- Chronic neurological sequelae (basal ganglia calcifications leading to Parkinsonism-like symptoms, dystonia).
- Severe cataracts.
- Significant intellectual disability.
- Extensive subcutaneous ossifications.
- Progression of skeletal deformities.
Atypical Presentations:
- Variable penetrance of AHO features, even within the same family.
- Isolated hypocalcemia without obvious AHO features (e.g., PHP Type Ib).
- Patients may present primarily with endocrine dysfunction (e.g., hypothyroidism) before hypocalcemia is recognized.

Physical Examination

Inspection:
- Assess for short stature and truncal obesity.
- Observe facial features: round face, short neck.
- Examine hands and feet for brachydactyly, specifically the "knuckle dimple sign" where the 4th and 5th metacarpal heads do not protrude when making a fist.
- Look for cataracts (slit lamp examination for subcapsular cataracts).
- Inspect skin for subcutaneous nodules or plaques consistent with ossifications.
- Assess dental development for enamel hypoplasia or malocclusion.
- Note signs of hypothyroidism (e.g., coarse hair, dry skin, bradycardia).
Palpation:
- Palpate for subcutaneous ossifications/calcifications, especially over joints or pressure points.
- Assess for Chvostek's sign (facial muscle twitching upon tapping facial nerve anterior to earlobe) and Trousseau's sign (carpal spasm induced by inflating a blood pressure cuff above systolic pressure for 3 minutes). These indicate neuromuscular excitability due to hypocalcemia.
Special Tests:
- Neurological examination to assess for seizures, tremors, dystonia, or other movement disorders, and cognitive function.

Diagnostic Approach

History Taking

Key Questions:
- Symptoms of hypocalcemia: Paresthesias, muscle cramps, tetany, seizures, laryngeal spasm.
- Developmental history: Age of onset of symptoms, cognitive development, school performance.
- Growth history: Height, weight, growth velocity, puberty onset.
- Family history: Any relatives with similar features (short stature, obesity, brachydactyly, intellectual disability, seizures, thyroid problems) or known GNAS mutations.
- History of thyroid dysfunction or other endocrine issues.
- Dental problems.
- Vision changes (cataracts).
- History of subcutaneous nodules.
Red Flags:
- Recurrent seizures in infancy or childhood with no clear etiology.
- Hypocalcemia with hyperphosphatemia and high PTH levels.
- Presence of AHO features (brachydactyly, short stature, obesity) in a patient with hypocalcemia.
- Family history of PHP or AHO.

Laboratory Tests

First-Line:
- Serum Calcium (total and ionized): Low.
- Serum Phosphate: Elevated.
- Serum PTH (Intact PTH): Elevated (inappropriately high for the degree of hypocalcemia, indicating resistance rather than deficiency).
- Serum Albumin: For correction of total calcium if necessary.
- Serum Magnesium: Rule out concomitant hypomagnesemia, which can exacerbate hypocalcemia and cause PTH resistance itself.
- Serum 25-hydroxyvitamin D [25(OH)D]: Assess vitamin D status. Often normal or low, but not the primary cause.
- Serum 1,25-dihydroxyvitamin D [1,25(OH)2D]: Typically low or low-normal for the elevated PTH level, reflecting impaired renal 1-alpha hydroxylase activity.
- TSH, Free T4: To assess for TSH resistance (elevated TSH with normal or low free T4 in PHP Ia/Ic).
- Gonadotropins (FSH, LH) and Sex Hormones: To assess for gonadal dysfunction (in PHP Ia/Ic).
- Urine Calcium (random or 24-hour): Initially to assess renal calcium handling. Important for monitoring during treatment to prevent hypercalciuria.
- Creatinine, BUN: To assess renal function.
Confirmatory:
- PTH Resistance Test (Ellsworth-Howard Test): Historically used but rarely performed now. Involves intravenous administration of exogenous PTH (e.g., recombinant human PTH 1-34) and measuring urinary cAMP and phosphate excretion. In PHP, the urinary cAMP response (and often phosphate response) is blunted. This test is labor-intensive and has largely been replaced by genetic testing.
- Genetic Testing:
  - GNAS gene sequencing: To identify heterozygous inactivating mutations for PHP Type Ia/Ic and PPHP.
  - Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA): To identify epigenetic defects (loss of methylation) at the GNAS locus for PHP Type Ib. This is the preferred test for suspected PHP1B.
Monitoring:
- Serum Calcium, Phosphate, PTH, Albumin: Weekly to monthly initially, then every 3-6 months once stable.
- 25(OH)D, 1,25(OH)2D: Periodically.
- 24-hour Urinary Calcium Excretion: Crucial to monitor for hypercalciuria (target < 4 mg/kg/day or calcium/creatinine ratio < 0.2-0.25 in children), which can lead to nephrocalcinosis/nephrolithiasis. Monitor monthly initially, then every 3-6 months.
- TSH, Free T4: Annually or as clinically indicated.
- Renal Function (Creatinine, GFR): Annually.

Imaging

Recommended:
- Hand X-rays: To confirm brachydactyly (shortening of 4th and 5th metacarpals/metatarsals) and look for cone-shaped epiphyses or other bone abnormalities.
- Skull X-ray or CT/MRI Brain: To evaluate for basal ganglia calcifications (common finding in chronic hypocalcemia, especially in PHP Ia).
- Dental X-rays: To assess for enamel hypoplasia, blunted roots, delayed eruption.
- Renal Ultrasound: To screen for nephrocalcinosis or nephrolithiasis, which are potential complications of the disease and its treatment. Should be performed at diagnosis and annually or biannually.
Advanced:
- Bone Densitometry (DXA): To assess bone mineral density, especially in adults, as bone health can be affected despite high PTH levels (due to impaired bone remodeling in the setting of PTH resistance and mineral imbalances).
- Skeletal Survey: In cases of suspected Progressive Osseous Heteroplasia or extensive subcutaneous ossifications.

Management

The primary goal of management is to maintain serum calcium and phosphate levels within or close to the normal range, alleviate symptoms, prevent complications, and address associated endocrine deficiencies. Lifelong treatment is typically required.

Acute Management (for symptomatic hypocalcemia/hypocalcemic crisis)

Immediate:
- Intravenous Calcium Gluconate: For patients with acute symptomatic hypocalcemia (tetany, seizures, laryngeal spasm, cardiac arrhythmias, QTc prolongation).
  - Adults: 1-2 grams of 10% calcium gluconate (10-20 mL) IV over 10-20 minutes. Contains 90-180 mg of elemental calcium.
  - Children: 0.5-1 mL/kg of 10% calcium gluconate IV over 5-10 minutes (max 10 mL).
- Monitor ECG continuously during IV calcium administration for bradycardia or arrhythmias.
Stabilization:
- Following initial bolus, initiate a continuous intravenous calcium infusion to maintain normocalcemia.
  - Adults: 0.5-2 mg elemental calcium/kg/hour (e.g., 20-50 mL of 10% calcium gluconate diluted in 500-1000 mL D5W or NS, infused at appropriate rate).
  - Children: 0.5-0.75 mg elemental calcium/kg/hour.
- Correct hypomagnesemia if present, as it can worsen hypocalcemia and cause PTH resistance. IV magnesium sulfate may be required.
  - Adults: 1-2 grams of magnesium sulfate IV over 1-2 hours.
  - Children: 25-50 mg/kg IV over 2-4 hours.
- Begin oral calcium and active vitamin D as soon as the patient can tolerate oral intake and the acute symptoms are controlled.
Emergency:
- Airway management (intubation) for severe laryngeal spasm.
- Anticonvulsants for seizures if calcium correction alone is insufficient, though calcium is usually effective.

Chronic Management

Pharmacological:
- Calcium Supplements:
  - Oral calcium carbonate, calcium citrate, or other salts. Dosage depends on dietary intake and calcium levels.
  - Dosage: Typically 1-3 grams elemental calcium daily in divided doses (e.g., 500 mg - 1000 mg 2-3 times daily).
  - Aim for low-normal serum calcium (e.g., 8.0-8.5 mg/dL or 2.0-2.12 mmol/L) to prevent hypercalciuria.
- Active Vitamin D Analogs:
  - Necessary to promote calcium absorption and bone mineralization, bypassing the PTH resistance effect on 1-alpha hydroxylase.
  - Calcitriol (1,25-dihydroxyvitamin D3): The most commonly used.
    - Dosage: 0.25-2 mcg daily, often divided twice daily. Start at 0.25 mcg once or twice daily and titrate slowly (every 1-2 weeks) based on serum calcium, phosphate, and urinary calcium.
  - Alfacalcidol (1-alpha-hydroxyvitamin D3): A prodrug that is converted to calcitriol in the liver. Similar efficacy to calcitriol.
    - Dosage: 0.25-2 mcg daily.
  - Doxercalciferol, Paricalcitol: Less commonly used for PHP but are other active vitamin D analogs.
- Thyroid Hormone Replacement: For patients with TSH resistance (in PHP Type Ia/Ic), typically levothyroxine. Dosage guided by TSH and free T4 levels.
- Growth Hormone (GH) Replacement: For significant short stature due to GHRH resistance in PHP Ia, consider if growth velocity is severely impaired. (Specialist endocrinology consultation recommended).
- Gonadotropin/Sex Hormone Replacement: For gonadal dysfunction in PHP Ia, consider as clinically indicated for pubertal induction or fertility.
Non-pharmacological:
- Dietary considerations: Patients typically do not need to restrict dietary phosphate, as PTH resistance already leads to hyperphosphatemia. Adequate hydration is important.
- Patient and Family Education: Emphasize lifelong adherence to medication, recognition of symptoms of hypocalcemia or hypercalcemia, and importance of regular monitoring.
Monitoring:
- Frequent Blood Tests: Initially weekly to monthly until stable, then every 3-6 months.
  - Serum Calcium (total and ionized), Phosphate, Albumin.
  - Intact PTH (PTH levels usually remain elevated despite treatment, reflecting ongoing resistance; the goal is calcium/phosphate normalization, not PTH normalization).
  - Serum Magnesium, Creatinine, eGFR.
- Urinary Calcium: 24-hour urinary calcium excretion should be monitored regularly (e.g., every 1-3 months initially, then every 6-12 months once stable) to prevent hypercalciuria, which is a significant risk factor for nephrocalcinosis and nephrolithiasis. Target urinary calcium excretion should be < 4 mg/kg/day or urinary calcium/creatinine ratio < 0.2-0.25 mg/mg (in children) or < 0.2 g/g (in adults). Thiazide diuretics may be used in cases of persistent hypercalciuria.
- Renal Ultrasound: Annually or biannually to screen for nephrocalcinosis and nephrolithiasis.
- Bone Densitometry (DXA): Every 1-2 years in adults to monitor bone health.
- Ophthalmologic Examination: Annually to screen for cataracts.
- Neurodevelopmental Assessment: Especially in children with PHP Ia/Ic, to identify and address cognitive or developmental delays.

Treatment Algorithms

First-Line:
1. Oral Calcium Supplements: To provide adequate calcium intake.
2. Active Vitamin D Analogs (Calcitriol or Alfacalcidol): To enhance calcium absorption and manage hypocalcemia. Start with low doses and titrate gradually to achieve serum calcium levels in the low-normal range (e.g., 8.0-8.5 mg/dL) while avoiding hypercalciuria.
Second-Line:
1. Optimize Dosing: Adjust doses of calcium and active vitamin D based on serial monitoring of serum calcium, phosphate, and urinary calcium.
2. Thiazide Diuretics (e.g., Hydrochlorothiazide): If hypercalciuria persists despite maintaining low-normal serum calcium, or if nephrocalcinosis develops, thiazide diuretics can be added to reduce urinary calcium excretion.
  - Dosage: e.g., Hydrochlorothiazide 0.5-1 mg/kg/day in 1-2 divided doses. Monitor for hypokalemia and hypomagnesemia.
Refractory Cases:
1. Re-evaluate Adherence: Non-adherence to medication is a common cause of refractory symptoms.
2. Review Magnesium Status: Ensure magnesium levels are optimal.
3. Consider PTH Analog (e.g., Teriparatide): In select cases of severe, poorly controlled PHP, particularly those with significant bone disease, subcutaneous ossifications, or high risk of hypercalciuria despite conventional therapy, an off-label trial of PTH analogs may be considered. These agents can reduce calcium and active vitamin D requirements, and potentially improve bone metabolism, but require specialized management and further research is ongoing.

Complications

Common:
- Cataracts: Especially subcapsular, due to chronic hypocalcemia.
- Basal Ganglia Calcifications: A common finding on brain imaging in chronic hypocalcemia, contributing to neurological symptoms like dystonia, Parkinsonism, and headaches.
- Intellectual Disability/Developmental Delay: Prevalent in PHP Type Ia/Ic, varying in severity.
- Dental Abnormalities: Enamel hypoplasia, delayed eruption, blunted roots, hypodontia.
- Obesity and Short Stature: In patients with AHO.
- Hypothyroidism: Due to TSH resistance (PHP Ia/Ic).
- Gonadal Dysfunction: Hypogonadism (PHP Ia/Ic).
- Nephrocalcinosis/Nephrolithiasis: A significant complication of both the underlying disease and chronic treatment with high doses of calcium and active vitamin D, leading to chronic kidney disease.
Serious:
- Hypocalcemic Crisis: Severe tetany, seizures, laryngeal spasm, cardiac arrhythmias (QT prolongation, Torsades de Pointes), which can be life-threatening.
- Chronic Kidney Disease: Due to persistent nephrocalcinosis and nephrolithiasis.
- Progression of Subcutaneous Ossifications: Can be painful, functionally limiting, and disfiguring, especially in POH.
Long-term:
- Osteoporosis or osteitis fibrosa cystica (rare, paradoxical in face of high PTH): Bone health can be complex, requiring careful monitoring.
- Chronic neurological deficits.
- Increased cardiovascular risk (e.g., hypertension, dyslipidemia) possibly related to obesity in AHO.

Prognosis

Factors: The prognosis of PHP depends on the specific genetic subtype, the severity of hypocalcemia and associated features, the age at diagnosis, and adherence to treatment. Early diagnosis and consistent management are critical.
Survival: With appropriate and consistent treatment, the life expectancy for most patients with PHP is generally good and can be near normal. However, complications such as severe seizures, renal failure from nephrocalcinosis, or severe cardiac arrhythmias can impact survival if not adequately managed.
Quality of Life: Quality of life can be significantly affected, particularly in patients with PHP Type Ia/Ic due to AHO features (short stature, obesity, physical deformities from subcutaneous ossifications), intellectual disability, and the need for lifelong medication and frequent monitoring. The cosmetic impact of AHO features and neurological complications can be substantial. Good adherence to therapy and multidisciplinary support can improve outcomes.

Prevention

Primary:
- Genetic Counseling: For families with a known history of PHP or a diagnosed individual, genetic counseling is crucial to inform about inheritance patterns, recurrence risks, and family planning options. Prenatal diagnosis may be available for known mutations.
Secondary:
- Early Diagnosis: Prompt recognition of signs and symptoms (especially hypocalcemia with high PTH and AHO features) allows for early intervention to prevent severe acute complications (seizures, cardiac arrest) and mitigate chronic complications like intellectual disability and cataracts. Newborn screening for calcium/phosphate abnormalities is not routinely performed.
- Aggressive Management of Hypocalcemia: Maintaining normocalcemia from early life helps prevent the progression of neurological and ocular complications.
Tertiary:
- Preventing Complications of Treatment: Meticulous monitoring of serum and urinary calcium is essential to prevent iatrogenic hypercalciuria, nephrocalcinosis, and subsequent chronic kidney disease, which are common and serious long-term complications of therapy.
- Regular Screening for Associated Conditions: Routine monitoring for hypothyroidism, gonadal dysfunction, and other endocrine issues in PHP Ia/Ic allows for timely treatment.
- Multidisciplinary Care: Involving endocrinologists, geneticists, nephrologists, neurologists, ophthalmologists, and developmental specialists ensures comprehensive management and early intervention for complications.

Special Populations

Pediatric:
- Diagnosis: Often presents in infancy or early childhood with seizures, developmental delay, or AHO features.
- Management: Doses of calcium and active vitamin D must be carefully calculated based on weight and titrated frequently. Close monitoring of growth and neurodevelopment is crucial. Early intervention programs for developmental delays are important.
- Monitoring: More frequent monitoring of serum and urinary electrolytes in infants and young children due to rapid growth and metabolism. Calcium-to-creatinine ratio is preferred for urinary calcium assessment in children not yet toilet-trained for 24-hour collection.
Geriatric:
- Considerations: Renal function may decline with age, affecting vitamin D metabolism and increasing risk of nephrocalcinosis with treatment. Polypharmacy and increased fall risk need to be considered in relation to hypocalcemia symptoms.
- Bone Health: Increased vigilance for osteoporosis, especially if bone density is affected by long-term disease.
Pregnancy:
- Increased Calcium and Vitamin D Requirements: Maternal calcium requirements increase significantly during pregnancy, especially in the third trimester, to support fetal skeletal development. This often necessitates increased doses of calcium and active vitamin D.
- Frequent Monitoring: Serum calcium levels must be meticulously monitored (e.g., monthly or more often) to maintain maternal normocalcemia. Poorly controlled maternal hypocalcemia can lead to fetal hyperparathyroidism, skeletal demineralization, and rickets in the neonate.
- Delivery: No specific recommendations, but normal vaginal delivery is typically safe.
- Lactation: Calcium requirements remain elevated during lactation, necessitating continued vigilance with medication dosing.
Comorbidities:
- Hypothyroidism: If TSH resistance is present (PHP Ia/Ic), require lifelong levothyroxine replacement.
- Obesity: Common in PHP Ia/Ic. Management should include lifestyle interventions and consideration of weight management strategies.
- Intellectual Disability: Requires educational support and adaptive strategies.
- Chronic Kidney Disease: Requires careful dose adjustment of calcium and active vitamin D, and close monitoring of renal function, especially if nephrocalcinosis develops.

Clinical Pearls

Diagnostic:
- Always consider PHP in a patient (especially a child) presenting with hypocalcemia AND hyperphosphatemia, even if PTH levels are within the "normal" range (as this is still inappropriately high given the hypocalcemia). The key is the unresponsiveness to PTH.
- AHO features (short stature, obesity, round face, brachydactyly, subcutaneous ossifications) are a strong clue for PHP Type Ia/Ic, but their absence does not rule out PHP (e.g., PHP Ib).
- Look for the "knuckle dimple sign" (absence of prominent knuckles over the 4th/5th metacarpals when making a fist) – a classic sign of brachydactyly in AHO.
Treatment:
- The goal of treatment is to normalize serum calcium and phosphate, not necessarily to normalize PTH (which often remains elevated).
- Aim for low-normal serum calcium to minimize the risk of hypercalciuria and nephrocalcinosis.
- Lifelong treatment with calcium and active vitamin D is usually required.
- Close monitoring of 24-hour urinary calcium is paramount to prevent long-term renal complications from over-treatment.
Pitfalls:
- Misdiagnosis as Primary Hypoparathyroidism: In primary hypoparathyroidism, PTH levels are low or undetectable in the presence of hypocalcemia and hyperphosphatemia. In PHP, PTH is high. Confusing these leads to incorrect treatment.
- Over-treatment leading to Hypercalciuria: Excessive calcium and active vitamin D supplementation can lead to hypercalciuria, which can cause nephrocalcinosis, nephrolithiasis, and progressive renal impairment. This is a common and preventable complication.
- Failure to Address Associated Endocrine Deficiencies: In PHP Ia/Ic, overlooking TSH resistance or gonadal dysfunction can lead to additional morbidity.
- Neglecting Magnesemia: Hypomagnesemia can induce PTH resistance and worsen hypocalcemia, thus it should always be corrected.

Recent Updates

Guidelines: Recent Endocrine Society guidelines (2022) for the diagnosis and management of primary hypoparathyroidism now include specific considerations for PHP, emphasizing the distinct pathophysiology and management goals. They highlight the role of genetic testing for definitive diagnosis and subclassification.
Evidence:
- Increased understanding of the genetic and epigenetic landscape of GNAS defects has refined the classification and diagnostic approach, especially for PHP Type Ib.
- Ongoing research into the role of PTH analogs (e.g., teriparatide) in managing challenging cases of PHP, particularly those with severe subcutaneous ossifications or persistent hypercalciuria, although not yet routine first-line therapy.
- Advanced imaging techniques and long-term follow-up studies are providing better insights into the progression of complications like basal ganglia calcifications and their neurological sequelae.
Controversies:
- Optimal Target Calcium Range: While a low-normal serum calcium target is widely accepted to minimize hypercalciuria, the precise optimal range for individual patients, balancing symptom control and renal safety, remains a subject of ongoing clinical judgment.
- Role of PTH Analogs: The long-term efficacy and safety of PTH analogs in PHP are still being evaluated. Their use is currently considered off-label and requires specialized expertise.

Key References

Guidelines:
- Brandao J, et al. Management of Hypoparathyroidism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2022 Mar 24;107(4):817-843. (Includes sections on PHP)
- Levine MA. An update on the clinical and molecular characteristics of pseudohypoparathyroidism. Curr Osteoporos Rep. 2012 Jun;10(2):112-9.
Studies:
- Tafaj O, et al. Albright's Hereditary Osteodystrophy. In: Feingold KR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. 2016 Oct 14.
- Thakker RV. Genetics of Parathyroid Tumours. J Inherit Metab Dis. 2012 Aug;35(4):593-605. (Broader review of parathyroid genetics, including PHP)
- Shoemaker AH, et al. Pseudohypoparathyroidism. 2007 Aug 22 [Updated 2019 Jul 25]. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023.
Reviews:
- Underwood JN, et al. Genetic and molecular pathophysiology of Pseudohypoparathyroidism. Semin Cell Dev Biol. 2015 May;41:147-56.
- Linglart A, et al. GNAS-related disorders. Best Pract Res Clin Endocrinol Metab. 2011 Dec;25(6):951-64.